MENU
+Compare
GERN
Stock ticker: NASDAQ
AS OF
Dec 26, 10:33 AM (EDT)
Price
$1.38
Change
-$0.02 (-1.43%)
Capitalization
893.7M

GERN Geron Corp Forecast, Technical & Fundamental Analysis

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments... Show more

Industry: #Biotechnology
GERN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GERN with price predictions
Dec 24, 2025

GERN in downward trend: price may decline as a result of having broken its higher Bollinger Band on December 11, 2025

GERN broke above its upper Bollinger Band on December 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In of the 35 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GERN moved out of overbought territory on December 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where GERN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 28, 2025. You may want to consider a long position or call options on GERN as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GERN just turned positive on November 24, 2025. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

GERN moved above its 50-day moving average on December 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GERN crossed bullishly above the 50-day moving average on December 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 130 cases where GERN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GERN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.593) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (5.084) is also within normal values, averaging (311.015).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GERN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

GERN is expected to report earnings to -2 cents per share on March 12

Geron Corp GERN Stock Earnings Reports
Q4'25
Est.
$-0.03
Q3'25
Est.
$-0.03
Q2'25
Beat
by $0.01
Q1'25
Est.
$-0.03
Q4'24
Missed
by $0.01
The last earnings report on November 05 showed earnings per share of -2 cents, meeting the estimate of -2 cents. With 2.58M shares outstanding, the current market capitalization sits at 893.70M.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products for cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
919 East Hillsdale Boulevard
Phone
+1 650 473-7700
Employees
141
Web
https://www.geron.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSJAX65.760.43
+0.66%
Cohen & Steers Realty Shares A
GMUEX14.750.06
+0.41%
GMO US Equity III
EMSLX18.990.07
+0.37%
Shelton Emerging Markets Investor
VCGRX22.490.06
+0.27%
Virtus KAR Capital Growth R6
GGEZX26.550.05
+0.19%
GuideStone Funds Growth Equity Investor

GERN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
+5.26%
SER - GERN
66%
Loosely correlated
-3.17%
LIANY - GERN
53%
Loosely correlated
-7.14%
VCYT - GERN
44%
Loosely correlated
-0.35%
SYRE - GERN
40%
Loosely correlated
-0.54%
UTHR - GERN
37%
Loosely correlated
+0.82%
More